Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-pentanone + AAV-hBDNF
- Development stage
- Unknown
- Lead developer
- Shiyan Taihe Hospital
- Modality
- Gene Therapies, Small Molecules
- Administration
- Intracranial, Inhalation
01
Overview
3-pentanone + AAV-hBDNF is an experimental combination therapy developed by Shiyan Taihe Hospital (Taihe Hospital of Hubei University of Medicine) for the treatment of severe disorders of consciousness (DOC), including vegetative state (VS) and minimal consciousness state (MCS). The therapy utilizes a dual-action approach: a gene therapy component consisting of an adeno-associated virus (AAV) vector carrying the human brain-derived neurotrophic factor (hBDNF) gene, and a small molecule component, 3-pentanone (also known as diethyl ketone). The AAV-hBDNF is typically administered via intracranial injection into targeted brain regions such as the thalamus to promote neuronal survival, synaptic plasticity, and the repair of neural circuits. 3-pentanone is employed as a potent olfactory stimulant to activate the olfactory-thalamic-cortical pathway, aiming to enhance arousal and awareness in patients. This combination seeks to synergistically address the structural and functional deficits underlying persistent consciousness disorders.
- Other names
- dipentanone + gene therapy virus3-pentanone + AAV-BDNFdiethyl ketone + AAV-hBDNF3-pentanone + adeno-associated virus-human brain-derived neurotrophic factor
02
Targets
OR (Olfactory receptors)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on 3-pentanone + AAV-hBDNF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-pentanone + AAV-hBDNF.